Capital Fund Management S.A. Puma Biotechnology, Inc. Transaction History

Capital Fund Management S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$2.85 - $6.58 $104,612 - $241,525	-36,706 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.63 - $9.39 $10,919 - $15,465	1,647 Added 4.7%	36,706 $257,000
Q2 2021 Aug 12, 2021	BUY	$8.98 - $11.6 $14,673 - $18,954	1,634 Added 4.89%	35,059 $321,000
Q1 2021 May 14, 2021	BUY	$9.38 - $13.63 $10,402 - $15,115	1,109 Added 3.43%	33,425 $324,000
Q4 2020 Feb 12, 2021	BUY	$7.78 - $12.13 $70,167 - $109,400	9,019 Added 38.71%	32,316 $331,000
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $221,321 - $259,528	23,297 New	23,297 $235,000
Q3 2019 Nov 13, 2019	SELL	$8.75 - $12.85 $826,341 - $1.21 Million	-94,439 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$12.3 - $35.76 $1.16 Million - $3.38 Million	94,439 New	94,439 $1.2 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $412,123 - $598,679	-10,003 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $714,405 - $1.01 Million	-14,791 Reduced 59.66%	10,003 $592,000
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $1.48 Million - $2.46 Million	24,794 New	24,794 $1.69 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.